October 16, 2023
BioNTech evaluates impact of Pfizer’s wirte-offs on financial results
BioNTech is evaluating the potential impact of Pfizer’s write-offs and other charges related to COMIRNATY on its financial results.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
October 13, 2023
Sanofi: amlitelimab significantly improved signs and symptoms of moderate-to-severe atopic dermatitis
Positive results from a Phase 2b study (STREAM-AD) showed that amlitelimab significantly improved signs and symptoms of moderate-to-severe atopic dermatitis in adults whose disease cannot be adequately controlled with topical medications or for whom topical medications are not a recommended treatment approach.
October 13, 2023
CHMP recognizes urgent medical need for treating Duchenne patients
CHMP has adopted a positive opinion in favor of approval of a Swiss specialty pharmaceutical company Santhera Pharmaceuticals’ AGAMREE (vamorolone) for the treatment of Duchenne Muscular Dystrophy patients aged 4 years and older.
October 6, 2023
Medexprim appoints Chief Product and Technical Officer
Medexprim has appointed Montaine Marteau as Chief Product and Technical Officer (CPTO), concurrently with her integration into the company’s Executive Committee, alongside Romain Cazavan, Nicolas Dubost and Fabrice Pillon.
October 5, 2023
NICE recommends Jardiance for use as an option for chronic heart failure
The National Institute for Health and Care Excellence (NICE) announced Thursday that empagliflozin (Jardiance) is recommended for use as an option for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults.
October 5, 2023
AstraZeneca settles Nexium and Prilosec product liability litigations
AstraZeneca said Tuesday it has made agreements in the product liability litigations related to Nexium and Prilosec. The company said…
October 4, 2023
Moderna’s combo vaccine shows strong immunogenicity against influenza and COVID-19
Moderna announced Wednesday positive results from a clinical trial of mRNA-1083, its combination mRNA combination flu/COVID vaccine.
October 4, 2023
Mainz Biomed launches ColoAlert with Bioclinica in Romania
Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, has launched its flagship product, ColoAlert — a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) – with its partner Bioclinica, a leader in the Romanian healthcare sector.
October 3, 2023
Exscientia sees maintaining cash runway well into 2026
Exscientia provided Tuesday an update on its pipeline prioritisation strategy designed to further strengthen the Company’s focus, investment and infrastructure on programmes of greatest potential for differentiation and value creation, outlinging strategy which will support continued investment into market-leading technology while maintaining cash runway well into 2026.
October 3, 2023
Cancer cases and deaths on the rise in the EU
New cancer cases rose by 2.3 % compared to 2020, to reach 2.74 million in 2022. Similarly, cancer deaths went up by 2.4 % compared to 2020, according to the European Commission’s estimates published in the European Cancer Information System (ECIS).